Loading...

Major Indexes

Financial Statements

Cleveland BioLabs Inc.

Cleveland BioLabs Inc. (CBLI)

$2.17
-0.08 (-3.56%)

Income Statement

Quarter data
Download CBLI income statement Download CBLI income statement Download CBLI income statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Earnings Per Share Diluted -0.82-0.00-0.12-0.49-0.380.60-1.79-0.24-0.87-0.32-0.28
Net Profit Margin -179.57-1.74-0.46-5.11-2.030.44-4.67-0.76-4.98-3.17-3.38
Weighted Average Shares Outstanding 15.6426.1832.5635.7511.3511.3511.3511.3511.3511.3511.35
Revenue 71.4315,331.578.793.578.493.702.713.521.951.140.92
Weighted Average Shares Outstanding (Diluted) 15.6426.1835.6637.3945.002.707.0610.9911.1911.2911.30
Gross Profit 71.4315,331.578.793.578.493.702.713.521.951.140.92
Dividend per Share -----------
Operating Income -6,382.93-10,737.20-25.11-30.05-23.08-14.42-10.79-6.36-5.60-4.80-2.55
Gross Margin 1.001.001.001.001.001.001.001.001.001.001.00
Income Tax Expense -----------
EBIT Margin -84.36-0.67-2.63-8.28-2.66-3.67-3.88-1.79-2.86-4.20-2.75
Net Income -12,826.41-26,671.86-4.01-18.23-17.261.63-12.64-2.66-9.71-3.61-3.11
Cost of Revenue -----------
Earnings Before Tax Margin -179.57-1.74-0.581.08-2.420.48-4.81-0.78-5.02-3.38-3.36
EBIT -6,382.93-10,737.20-25.11-30.05-23.08-14.42-10.79-6.36-5.60-4.80-2.55
EBITDA -6,025.36-10,347.76-23.10-29.57-22.61-13.58-10.52-6.29-5.58-4.78-2.54
Profit Margin -179.57-1.74-0.46-5.11-2.030.44-4.67-0.76-4.98-3.17-3.38
Operating Expenses 20,728.8426,068.7633.9033.6231.5618.1213.509.877.555.943.47
Earnings Per Share Basic -0.82-0.00-0.12-0.49-0.380.60-1.79-0.24-0.87-0.32-0.28
Earnings before Tax -12,826.41-26,671.86-5.083.84-20.551.78-13.02-2.74-9.77-3.85-3.10
Interest Expense -1.96----------

Balance Sheet Statement

Quarter data
Download CBLI balance shet statement Download CBLI balance sheet statement Download CBLI balance sheet statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Short-term debt ---0.070.352.64-----
Other Assets 1,818.372,135.521.12-3.546.270.190.070.050.060.08
Total current liabilities 13,354.3430,418.639.8811.435.996.535.843.112.210.911.52
Cash and cash equivalents 963.1010,918.5422.8725.6510.053.105.926.904.233.601.13
Long-term debt 1,405.71136.161.220.100.011.501.581.820.970.690.78
Cash and short-term investments 963.1011,377.9028.3928.2910.353.1019.6215.258.794.101.58
Total debt 1,405.71136.161.220.170.364.141.581.820.970.690.78
Inventories -----------
Deferred revenue 2,329.62349.11-3.311.070.160.01----
Goodwill and Intangible Assets -----------
Total non-current liabilities 1,405.71136.161.223.510.021.501.581.820.010.010.78
Total non-current assets --1.122.603.546.270.190.070.050.060.03
Total liabilities 6,553.851,968.1123.0725.6824.2211.4210.998.437.435.996.56
Total assets 6,553.8519,886.6032.1332.0114.709.8120.8815.969.634.532.04
Other comprehensive income --108.87123.86125.51132.69158.22158.77163.11163.16163.16
Short-term investments -459.365.522.630.314.2713.708.344.560.500.45
Property, Plant & Equipment Net --1.080.990.460.240.120.040.020.030.02
Net Debt 442.62-10,782.37-22.87-25.48-9.691.04-5.92-6.90-4.23-3.60-1.13
Investments -459.365.522.630.314.2713.708.344.560.500.45
Total shareholders equity -6,800.49-15,698.019.066.33-9.52-1.619.897.522.20-1.45-4.52
Retained earnings (deficit) ---100.07-118.30-135.56-133.94-147.98-150.74-160.45-164.06-167.17
Long-term investments -----------
Receivables -5,382.121.740.040.460.270.630.350.550.250.38
Payables 1,208.631,261.490.911.520.791.060.200.340.200.140.26
Total current assets 4,735.4817,751.0831.0129.4111.163.5520.6915.899.584.482.00

Cash Flow Statement

Quarter data
Download CBLI cash flow statement Download CBLI cash flow statement Download CBLI cash flow statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Investing Cash Flow 626.54-1,175.75-6.0723.430.56-1.79-10.285.673.893.970.16
Free Cash Flow --5,899.33-17.23-20.65-23.10-14.46-12.08-5.04-6.61-4.61-2.66
Depreciation & Amortization 357.57389.442.010.480.470.840.280.060.020.020.01
Net cash flow / Change in cash 663.259,955.4411.952.78-15.60-6.942.810.98-2.67-0.61-2.49
Effect of forex changes on cash --0.160.54-0.32-1.290.24-0.190.05-0.020.02
Financing Cash Flow 4,281.6617,065.0934.7721.527.2610.5924.940.54-0.06-
Dividend payments -936.64----------
Stock-based compensation --4.042.541.470.500.100.01---
Investment purchases ---5.52-5.22--1.41-16.87-17.23-8.63-7.74-1.24
Acquisitions and disposals -----------
Capital Expenditure --0.33--------
Operating Cash Flow --5,899.33-16.91-20.65-23.10-14.46-12.08-5.04-6.61-4.61-2.66

Retained Earning Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) ----100-118-136-134-148-151-160-164
Net Income -12,826-26,672-4-18-172-13-3-10-4-3
Stock Dividends 13,76326,672-96----1-0---
Dividend Paid -937----------
Retained Earnings ---100-118-136-134-148-151-160-164-167

PPE Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE ---11000000
Annual Depreciation --1-0-1-0-0-0-00-0
Capital Expenditure --0--------
Net PPE --110000000

Intangible and Goodwill Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) -----------
New Purchases ---6-5--1-17-17-9-8-1
Intangible and Goodwill -----------

Cleveland BioLabs Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Cleveland BioLabs Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.